Click to scroll back to the top
Houston_Methodist_logo-White.svg
Search.svg
Close_Menu.svg
result
Share on FacebookShare on TwitterShare on Linkedin

Active/Enrolling Clinical Trials

The Underwood Center reviews this list of active/enrolling clinical trials before publication. However, the status of the studies may change. Please contact the study coordinator to inquire about enrollment for your patient.
Disease / Condition
PI
Particulars of Eligible Patient Population
Intervention
Primary Coordinator
Contact
Chronic Inflammatory Diseases
Abraham, Bincy
Pregnant women who continue treatment with certolizumab pegol as per SOC during pregnancy
certolizumab pegol is SOC commercial treatment. Only intervention is blood samples during pregnancy and postpartum.
Melissa Whipple
mbwhipple@houstonmethodist.org
Crohn's Disease
Abraham, Bincy
Moderately to Severely Active Crohn's Disease
Ozanimod vs placebo
Melissa Whipple
mbwhipple@houstonmethodist.org
Crohn's Disease
Abraham, Bincy
Moderately to Severely Active Crohn's Disease
Guselkumab vs placebo
Melissa Whipple
mbwhipple@houstonmethodist.org
GERD
Kim, Min
Gastroesophageal Reflux Disease
LINX Reflux Management System
Aisha Matin
amatin@houstonmethodist.org
Gastroparesis
Dacha, Sunil
Gastroparesis and non-gastroparesis patients scheduled for upper endoscopy
EndoFLIP device
Melissa Whipple
mbwhipple@houstonmethodist.org
IBD
Abraham, Bincy
Pregnant women with IBD and their infants through 18 years old that have been exposed to a biologic, small molecule, or immunomodulator at any time through delivery.
N/A - Registry study with questionnaires and blood samples
Melissa Whipple
mbwhipple@houstonmethodist.org
IBD
Abraham, Bincy
IBD patients with UC or CD taking a new eligible immunosuppressant, biologic, or small molecue medication listed in protocolx
N/A - Registry study
Melissa Whipple
mbwhipple@houstonmethodist.org
IBD-Arthropathy
Abraham, Bincy
IBD Arthropathy with active joint symptoms who would be treated with celecoxib as SOC
Curcumin vs Celecoxib
Melissa Whipple
mbwhipple@houstonmethodist.org
HCC
Victor, David
Cirrhosis & early HCC
N/A - Biomarker study
Ahmed Elsaiey
aelsaiey@houstonmethodist.org
PSC
Victor, David
Primary Sclerosing Cholantitis (PSC) with Adult tchRO Score > 4
Volixibat vs Placebo
Miguel Valdivia y Alvarado
mvaldiviayalvarado@houstonmethodist.org
NASH
Victor, David
NASH (NAS > 4) with liver fibrosis (F1-F3)
BI 456906 vs placebo
Melissa Cherry
mrcherry@houstonmethodist.org
NASH

Victor, David
Compensated cirrhosis due to NASH (F4)
BMS-986263 vs placebo
Melissa Cherry
mrcherry@houstonmethodist.org
Alcoholic Hepatitis
Victor, David
Severe Alcoholic Hepatitis
DUR-928 vs placebo
Marcos De Olivera
mdeoliveira@houstonmethodist.org
NASH
Victor, David
NASH (NAS > 4) with liver fibrosis (F2-F3)
Semaglutide vs placebo
Melissa Cherry
mrcherry@houstonmethodist.org
NASH
Victor, David
NASH with liver fibrosis F2-F3)
Lanifibranor vs placebo
Melissa Cherry
mrcherry@houstonmethodist.org